Real-World Treatment Patterns and Survival Among Patients with Stage I-III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment.
Soo Jin SeungDaniel MoldaverShazia HassanIqra SyedMaryKate ShanahanGeoffrey LiuPublished in: Oncology and therapy (2024)
In Ontario, between 2010 and 2019, uptake of adjuvant therapy was low among patients with resected NSCLC, despite such therapy being associated with improved survival. Patients assumed to have recurred/relapsed had markedly reduced mOS, regardless of subsequent therapy, compared with those who did not relapse/recur. Novel peri-adjuvant treatment options are needed to enhance outcomes after lung resection.
Keyphrases
- small cell lung cancer
- end stage renal disease
- prognostic factors
- ejection fraction
- free survival
- acute lymphoblastic leukemia
- early stage
- acute myeloid leukemia
- lymph node
- stem cells
- diffuse large b cell lymphoma
- peritoneal dialysis
- quantum dots
- atrial fibrillation
- gold nanoparticles
- tyrosine kinase
- bone marrow
- acute coronary syndrome
- multiple myeloma
- room temperature